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ABSTRACT: Cesium−gold (Cs−Au) nanoparticles are shown to be
analytically advantageous for the electroanalytical sensing of dapoxetine
(DPX), a serotonin reuptake inhibitor used for the treatment of premature
ejaculation. The Cs−Au nanoparticles are electrically wired and supported
upon mass producible, economical screen-printed electrochemical sensing
platforms and are characterized electrochemically (cyclic voltammetry and
electrochemical impedance spectroscopy) and physiochemically (ﬁeld
emission scanning electron microscopy and energy dispersive X-ray
analysis). The face-centered design was applied to optimize the signiﬁcant
experimental factors by using square wave voltammetry. The Cs−Au-based
sensor is found to exhibit a large linear range (10−7 to 10−4 M) with a good
analytical linearity with the limits of detection and quantiﬁcation
corresponding to 2.50 × 10−10 and 8.33 × 10−8 M, respectively. The
developed sensor was successfully applied in the quantiﬁcation of DPX in
the presence of sildenaﬁl, both of which are commonly found within combined dose tablet pharmaceutical formulations. The
proposed DPX electrochemical Cs−Au-based sensor has the advantages of being single-shot and disposable and is shown to be
successful in determining DPX in pharmaceutical formulations, human urine, and serum samples with acceptable recoveries.
■ INTRODUCTION
The World Health Organization has deﬁned premature
ejaculation (PE) as “persistent or recurrent ejaculation with
minimal stimulation before or shortly af ter penetration and before
the person wishes it, over which the suf ferer has little or no
voluntary control, which causes the suf ferer and/or his partner
bother or distress.”1,2 PE prevails in over 20−30% of men,3 and
its probability is high in young adults and adolescents.4
Dapoxetine (DPX), [(S)-N,N-dimethyl-3-(naphthalene-1-
yloxy)-1-phenylpropan-1-amine] is a selective serotonin reup-
take inhibitor (SSRI)5 and was the ﬁrst drug approved in 2008
for PE treatment in seven European countries.5,6 Henceforth,
DPX has established marketing approval in 59 countries
worldwide. Its safety and eﬃcacy has also been substantiated by
an extensive clinical development program of PE treatment.5,7
Erectile dysfunction (ED) is another male-associated sexual
problem that is common in the elderly.8 The normal erectile
function may be impaired due to several physical or
psychological factors. Typical medications for ED9 promote
penile blood ﬂow, and enhance erectile function.6 Combina-
tions of SSRI and PDE-5 inhibitors are common in many sexual
health medications, in particular for PE.10,11
Regrettably, some of these medications may contain
incorrect doses, and moreover, many health supplements
contain undeclared agents. Food Drug Administration listed
355 undeclared sexual enhancement products, with ∼8% of
them containing undeclared DPX and other PDE-5 inhib-
itors.12 This underlying problem has a detrimental eﬀect on the
general health care. Mild dizziness to serious death has been
encountered as adverse eﬀects of these counterfeit medi-
cations.13 The widespread availability of male sexual enhancers
is a matter of concern.14,15 Hence, Lebel et al.16 developed a
fast screening liquid chromatography-mass spectrometry (MS)
methodology for the simultaneous identiﬁcation of 71 ED
active ingredients and 11 natural ingredients present in
counterfeited trademark products.16 Another study reported
the high-performance liquid chromatography isolation of DPX
from a health supplement powder sold in Singapore, along with
structural elucidation using nuclear magnetic resonance,
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infrared, high-resolution MS, and electrospray ionization mass
spectrometry.17
Chromatographic methods have been reported for the
analysis of DPX using either ultraviolet18−29 or ﬂuorescence
detection30 as well as capillary electrophoresis.31 Ultra-
performance liquid chromatography-MS/MS has also been
reported for the quantiﬁcation of DPX in biological ﬂuids.5,32
Obviously, all these reported instrumental techniques are costly
and demand professional training; analytically useful alter-
natives are sought after.
Electrochemical methods of analysis have shown to be
accurate, sensitive, and cost-eﬀective33 and can be applied for
the determination of diﬀerent analytes such as new psycho-
active substances,34 proteins,35 and opioid drugs.36,37 Simple,
rapid, inexpensive, and accurate testing devices should be made
available to meet patients’ convenience along with industrial
needs. In this regard, screen-printed electrodes (SPEs) have
been widely used for point-of-care testing applications with the
aim of satisfying inexpert users.38 SPEs have the beneﬁts of
being cost-eﬀective (due to having scales of economy),
portability, provide useful analytical outputs and can be easily
integrated within portable systems for on-site detection
analysis. Furthermore, SPEs can be rapidly modiﬁed with
nanomaterials to provide further enhancements in sensing
performance toward target analytes, which improve electro-
chemical activity and hence analytical performances.39,40 To
this end, we have electrochemically modiﬁed SPEs and tailored
the electrode surface to provide a nanoparticle-modiﬁed sensor
for the sensing of DPX. From this perspective, we have utilized
Au−Cs nanoparticle-modiﬁed SPEs to devise a new platform
for the sensing of DPX. This sensor is based on the
electrochemical codeposition of Au and Cs nanoparticles
onto the surface of SPEs. Note that to the best of our
knowledge, no dynamic electrochemical approaches have been
reported to date for the sensing of DPX, but potentiometric
sensing has been reported.41 The potential sensor was used for
the analysis of DPX alone and in the presence of coformulated
drug SIL simultaneously. The proposed electroanalytical
methodology was fully validated according to International
Conference on Harmonization (ICH) guidelines with further
selectivity assessment in the presence of SIL as a coformulated
PDE-5 inhibitor within pharmaceutical and biological samples.
■ RESULTS AND DISCUSSION
The electrochemical response of the Cs−Au/SPE was explored
to evaluate its potential as the basis of a DPX sensor. The cyclic
voltammetric response of the Cs−Au/SPE was explored toward
the electrochemical oxidation of DPX and compared to Au/
SPE, Cs/SPE, and a metallic-free unmodiﬁed SPE. Figure 1
depicts large and quantiﬁable electrochemical signatures in all
cases. The Cs−Au/SPE exhibits the highest voltammetric signal
(67.8 μA/+1.23 V) analytical response at the lowest (see
Experimental Section), and we surmise that upon the anodic
scan, the Cs−Au nanoparticles are not stripped oﬀ the
electrode surface, allowing the electrochemical oxidation of
DPX to occur. In the case of the Au/SPE and Cs/SPE, this is
not the situation, and the corresponding electrochemical
oxidation peaks of DPX are lower. Hence, the Cs−Au
nanoparticles exhibit a beneﬁcial synergistic eﬀect. The
Supporting Information provides further information on the
characterization of the electrode surfaces and determination of
the electrochemical active areas. The electrochemical properties
of the potential sensor were further corroborated through
electrochemical impedance spectroscopy (EIS). Figure S1
displays the EIS response for the bare SPE, Cs/SPE, Au/SPE,
and Cs−Au/SPE, where the bare SPE gives rise to a large
semicircle domain, indicating a high electron transfer resistance.
Upon modifying the SPE with Cs or Au, RCT exhibits a small
semicircle domain, indicating enhanced electrical conductivity.
In the case of the Cs−Au/SPE, RCT decreases, indicating an
increase in the electron-transfer kinetics. In summary, the
electron-transfer resistance decreases in the following order:
bare SPE < Cs/SPE < Au/SPE < Cs−Au/SPE, which conﬁrms
the observations reported above (Figure 1), indicating that the
combination of Au and Cs exhibits an excellent electrically
conducting material.
Next, the eﬀect of changing the solution pH upon the
electrochemical oxidation of DPX using the Cs−Au/SPE was
explored over the pH range of 2.0−7.0. As shown in Figure S4,
the peak potentials (Ep) voltammetrically shift toward a less
positive potential upon increasing the pH value from 2.0 to 7.0,
which can be attributed to the protonation/deprotonation of
DPX. Figure S4 reveals the relationships of the peak current
and peak potential with the solution pH, where the peak
current decreases with increasing pH; based upon this data, pH
2 Britton−Robinson (B−R) buﬀer was selected as the optimum
pH for further studies. Analysis of the voltammetric responses
(peak potential, Ep) displays a linear relationship with pH of the
buﬀer solution, which can be ﬁtted as Ep (V) = 1.35 V − 52.4
mV pH−1; coeﬃcient of determination R2 = 0.9997; the value
of 52.4 mV/pH is close to the theoretical value expected for an
equal electron and proton process. As depicted in Figure S4, a
well-developed anodic peak current was shown over the pH
range from 2.0 to 7.0. However, a small-developed second peak
starts to appear, which increases steadily with increasing pH.
Furthermore, on increasing the pH value up to 7.0, the ﬁrst
oxidation peak is observed to shift to a less-positive potential,
indicating the irreversible behavior of the oxidation process,
which is conﬁrmed by the cyclic voltammetric analysis (see
Figure 1). The corresponding peak decreases because of the
hindrance of the oxidation process due to the reduced
concentration of protons and strong adsorption of the oxidative
products of DPX upon the electrode surface. This suggests that
the H+ ions were involved in the oxidation of the DPX
Figure 1. Cyclic voltammograms of 1.0 mM DPX in the B−R buﬀer
(pH 2.0) at a scan rate of 0.10 V s−1 recorded using SPE, Cs/SPE, Au/
SPE, and Cs−Au/SPE.
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molecule, and the deprotonation step proceeds before the
electron-transfer step. The plot of the ﬁrst peak potential versus
pH exhibits a straight line between 2.0 and 7.0. From the
inspection of the molecular structure of DPX, it can be seen
that the anodic peak is likely because of the hydroxylation of
the benzene ring, as reported previously using mercury, boron-
doped diamond, and glassy carbon electrodes.42,43 DPX has
two suggested oxidation mechanism pathways. In acidic media,
from pH 2 → 4, one anodic peak appears. This peak is likely
because of the hydroxylation of the benzene ring.44 At pH
values 5.0 and above, another anodic peak starts to appear as
the DPX gives two separate anodic oxidation peaks. The second
anodic peak appears likely because of the deprotonation of
DPX and the formation of a cation radical via the loss of a
proton and an electron. This second oxidation process appears
in neutral and alkaline media because of the oxidation of the
secondary amine group.44 The decrease in the anodic signal
(peak current) is observed because of the appearance of the
second oxidation step occurring at less positive potentials.
Moreover, the anodic peak current of the ﬁrst peak reaches its
highest value at pH 2.0 in the form of a sharp peak and was
recorded as a single response in acidic media. On the basis of
the above data, pH 2.0 was selected for further electrochemical
measurements. Nyquist plots for the Cs−Au/SPE at diﬀerent
pH values are shown in Figure S4B. The semicircle diameter
and the impedance values increase with increasing pH,
indicating a decrease in the conductivity and giving the same
order of the cyclic voltammetry (CV) results.
Next, the eﬀect of varying the voltammetric scan rate upon
the electrochemical oxidation of DPX was investigated using
CV, as shown in Figure S5. The Cs−Au/SPE displays a linear
relationship between the voltammetric current (Ip) and the
square root of the scan rate (v1/2), as shown in Figure S5 (inset
A), suggesting that the electrochemical process is diﬀusion-
controlled. The data can be ﬁtted as Ip (μA) = −1.644 + 6.648v
(V s−1)−1/2 with a correlation coeﬃcient of 0.9993. The
electrochemical oxidation peak potential (Ep) is also dependent
upon the voltammetric scan rate, where increasing the scan rate
results in a shift to more positive potentials; the linear
relationship between Ep and log v can be described as Ep (mV)
= 491E (mV) + 155.2 (mV s−1) (R2 = 0.9998). Using the
Laviron45 equation for an irreversible electrochemical process,
the electrochemical parameters of the electrochemical oxidation
of DPX using the Cs−Au/SPE are found to be as follows: αn =
0.44, α = 0.44, Eo′ = 1.20, and ko = 26.9 s−1. On the basis of the
results obtained from the voltammetric experiments, the
number of electrons transferred (n) in the electrochemical
process was calculated and found to be one, which is in
agreement with the results obtained from the eﬀect of pH
described above.
Design of experiments for optimization is a beneﬁcial
technique to extract the eﬀects of factors upon certain
responses. As a common mathematical model for the prediction
of factors aﬀecting an analytical response, that is, in this case the
peak current, the response surface method (RSM) was applied,
which is an eﬃcient optimization procedure that saves both
cost and time.46,47 The RSM has the ability to estimate a
second-order prediction formula along with interaction eﬀects.
However, it requires a large number of experiments in
numerous factor designs. Therefore, factors should be limited
in the ﬁrst instance to apply the RSM. Screening for inﬂuential
factors such as pH, scan rate, along with deposition voltage and
time was experimentally conducted beforehand. This study
revealed that the scan rate, deposition time, and pH
substantially aﬀect the signal/current. A face-centered design
was applied, which is a special type of central composite design
for RSM optimization. Sixteen experiments were conducted in
random order, including eight experiments at the vertices of the
cube (code: + or −), six experiments on face axial points (i.e.,
axial value = 1; code: a or A), and a center point (code: 0)
repeated two times to improve the mathematical prediction
model (Table 1).
The mathematical prediction model for the current (I) was
calculated from the linear, quadratic, and interaction terms as
follows
= + + + −
− + − +
−
I X X X X
X X X X X X
X X
41.50 9.50 3.00 7.00 4.50
2.00 2.50 0.88 1.88
0.38
1 1
2
2 2
2
3 3
2
1 2 1 3
2 3
where X1, X2, and X3 are the scan rate, the deposition time and
pH, respectively. The coeﬃcient of determination (R2) of the
model was found to correspond to 0.92 with the root mean
square error found to be 4.67, indicating an adequate ﬁt of the
prediction model. Comparing the coeﬃcients of the main
eﬀects, we can conclude that the scan rate has the largest
signiﬁcant positive eﬀect (p = 0.0007), and hence response
would be maximized at a high level of this factor (50 mV/s).
Another signiﬁcant main eﬀect is the deposition time (p =
0.0032), the large positive coeﬃcient of X2 provides that the
long deposition time is favored. The last insigniﬁcant main
factor is pH with a negative coeﬃcient that in turn increases the
design’s target at its low level. All coeﬃcients of quadratic terms
are too small to be signiﬁcant as noticed response surface
curvatures in Figure 2. Note that the positive quadratic terms
were registered for the scan rate and pH, whereas a negative
one was present for the deposition time. Therefore, opposite
curvatures of contour lines were noticed in the deposition time
response function with other factors (Figure 2A,C). Trivial
interaction between the studied factors was also calculated in
the prediction model, however, the largest coeﬃcient of X1X3
Table 1. Levels of Studied Factors for Sixteen Experiments
in the RSM Design with the Obtained Response
factors’ level response
experiment
number pattern
scan rate
(mV/s)
deposition
time (s) pH
current
(μA)
1 +−+ 50 30 4 42
2 −+− 10 90 2 49
3 0 30 60 3 41
4 0a0 30 30 3 33
5 +−− 50 30 2 46
6 ++− 50 90 2 58
7 a00 10 60 3 31
8 −−− 10 30 2 29
9 −++ 10 90 4 36
10 A00 50 60 3 59
11 +++ 50 90 4 57
12 00A 30 60 4 47
13 0A0 30 90 3 42
14 0 30 60 3 40
15 −−+ 10 30 4 22
16 00a 30 60 2 42
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indicates a possible interaction between the scan rate and pH,
as observed in the contour line curvature in Figure 2B. The
ﬁnal optimization suggested that using a scan rate of 50 mV/s
and deposition time of 80 s at pH 2.0 would maximize the
obtained current.
The proposed Cs−Au/SPE-based sensor was next inves-
tigated through exploring the simultaneous detection of DPX
and SIL. The optimized conditions for DPX determination via
square wave voltammetry (SWV, pH 2.0, scan rate: 0.05 V s−1,
and 80 s for deposition) were used. The ICH guidelines48,49 for
method validation were followed for validation of this suggested
Figure 2. Surface plots summarizing the eﬀects of diﬀerent experimental parameters: (A) scan rate/deposition time, (B) pH/scan rate, and (C)
deposition time/pH upon the voltammetric current/analytical signal.
Figure 3. Square wave voltammograms using the Cs−Au/SPE sensors recorded in pH 2.0 B−R buﬀer corresponding to (A) 1.0 × 10−7 to 1.1 × 10−3
M DPX and (B) 5.0 × 10−8 to 1.1 × 10−3 SIL. (C) Square wave voltammograms of 6.6 × 10−7 to 1.0 × 10−4 M DPX in the presence of 5.0 × 10−8 to
6.0 × 10−5 M SIL at a scan rate of 0.05 V s−1 and their corresponding calibration curves.
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method. SWV experiments were performed using the Cs−Au/
SPE sensor in pH 2.0 B−R buﬀer solution containing various
individual concentrations of DPX. The calibration range used
was chosen based upon the likely practical range that DPX
concentrations will be encountered within real samples. The
SWV results are presented in Figure 3 with the corresponding
calibration plot (inset of Figure 3). The results show the peak
currents corresponding to the electrochemical oxidation of
DPX using the Cs−Au/SPE, which is found to be linearly
dependent on DPX concentrations over the range of 1.0 × 10−7
to 1.0 × 10−4 M [Ip (μA) = 0.147C (μM) + 2.104; R
2 =
0.9995]. The calculated limit of detection (LOD) and the limit
of quantitation (LOQ) were found to be 2.5 × 10−8 and 8.3 ×
10−8 M, respectively. Note that this is the ﬁrst voltammetric
approach, and previously only ion-selective electrodes were
reported with a linear range of 1.0 × 10−4 to 1.0 × 10−2 M, and
the LOD was reported to be 2.0 × 10−5 M,41 indicating that the
Cs−Au/SPE is analytically advantageous. The stability of the
Cs−Au/SPE was also explored, where the voltammetric peak
current was found not to change following storage in air for 7
days; the sensor was found to retain 98.94−99.07% of its initial
response. Furthermore, Figure 3B depicts the square wave
voltammograms for an array of varying concentrations of SIL
over the range of 2.5 × 10−8 to 5.0 × 10−5 M [Ip (μA) = 0.257C
(μM) + 1.102; R2 = 0.9991]. The calculated values of LOD and
LOQ were found to be 5.84 × 10−9 and 1.95 × 10−8,
respectively. The repeatability and intermediate precisions were
found to correspond to 0.891−0.902% and 0.957−1.08% for
DPX and SIL, respectively.
The speciﬁcity of the Cs−Au/SPE was next explored with its
electroanalytical response examined toward the sensing of DPX
in the presence of the frequently coformulated drug SIL. This
was performed by simultaneously changing the concentrations
of these drugs and recording the square wave voltammograms
on the Cs−Au/SPE. Figure 3C shows the voltammetric
response of using the Cs−Au/SPE sensor toward the sensing
of DPX in the presence of SIL. The results showed well-deﬁned
anodic peaks at potentials of +1.2 and +1.4 V, corresponding to
the oxidation of DPX and SIL, respectively, demonstrating that
the simultaneous determination of DPX and SIL is feasible. The
calibration plots (inset of Figure 3) are found to be linearly
related to the concentrations of DPX and SIL over the ranges
6.6 × 10−7 to 1.0 × 10−4 and 5.0 × 10−8 to 6.0 × 10−8 M,
respectively. The regression equations were Ip (μA) = 0.140C
(μM) + 0.910, R2 = 0.9991 and Ip (μA) = 0.234C (μM) +
0.931, R2 = 0.9990 for DPX and SIL, respectively. The
electroanalytical sensitivities of the Cs−Au/SPE sensor toward
the oxidation of DPX and SIL were found to be 0.140 and
0.234 μA/μM, respectively; these values are very close to the
value obtained for the independent determination of DPX and
SIL (0.147 and 0.257 μA/μM), demonstrating that the
simultaneous determination of DPX and SIL is possible with
useful analytical capabilities and sensitivities.
The presence of ascorbic acid (ASA) and uric acid (UA)
were also explored upon the electrochemical oxidation of DPX
(Figure S6) because these two analytes coexist in many
biological samples.50 The electrochemical oxidation of 6.5 ×
10−6 M DPX in the presence of 6.5 × 10−6 M ASA and UA
were investigated using the Cs−Au/SPE via SWV, as shown in
Figure S6, which demonstrates that these are far resolved from
the analytical peak of interest. The eﬀect of many substances
that can potentially interfere with the electroanalytical
determination of DPX were also examined. A range of potential
interferences were chosen, which are commonly found in
pharmaceutical formulations. Using a ﬁxed DPX concentration
of 6.5 × 10−6 M in pH 2.0 B−R buﬀer solution, each of these
substances was added, and the magnitude of the DPX signal
was monitored. From the chosen potential interfering
substances, none were found to interfere with the electro-
analytical sensing of DPX, and the tolerance limit was less than
±4% for each of the interference substances. The results
showed that 100-fold of sucrose, glucose, fructose, lactose, and
citric acid and 200-fold of potassium sorbate, stearic acid, talc
powder, magnesium stearate, povidone, microcrystalline
cellulose, starch, cellulose, colloidal silicon dioxide, and
croscarmellose sodium did not aﬀect the selectivity.
Calibration curves for the spiked plasma and urine were also
constructed. The obtained regression equation and related
validation parameters are reported in Table S1. The
determination of DPX and SIL in the spiked blood plasma,
urine, and the pharmaceutical sample (Joypox) tablets was
done using the Cs−Au/SPE sensors (Table 2). The above
analytical results indicate that the Cs−Au/SPE is a highly
accurate and sensitive sensor, which has further beneﬁts of not
requiring any intricate sample pretreatment and has potential as
an analytical methodology for the determination of DPX and
SIL in real samples.
■ CONCLUSIONS
In summary, we have reported for the ﬁrst time, the
electroanalytical sensing of DPX using a Au−Cs nanoparticle-
based sensor. This Cs−Au/SPE sensor exhibits low LOD and
LOQ with a wide linear range and is shown to determine DPX
in the existence of the frequently coformulated drug SIL
without any interference. The Cs−Au/SPE sensor has been
successfully applied for the determination of DPX within
Table 2. Determination of DPX in a Pharmaceutical
Formulation and Human Plasma Sample Using the New
Proposed Sensing Protocola
sample
amount added
(μM)
amount found
(μM)
apparent
recovery %
human blood plasma 8.00 8.01 100.13%
DPX 20.00 19.89 99.45%
70.00 69.97 99.96%
recovery % ± RSD 99.85% ± 0.354
SIL 0.40 0.399 99.75%
1.00 1.001 100.10%
40.00 39.95 99.88%
recovery % ± RSD 99.91% ± 0.177
human urine 6.00 5.96 99.33%
DPX 30.00 30.12 100.40%
80.00 80.09 100.11%
recovery % ± RSD 99.95% ± 0.553
SIL 0.60 0.597 99.50%
1.50 1.509 100.60%
30.00 30.25 100.83%
recovery % ± RSD 100.31% ± 0.711
Joypox
(60 mg/tablet)
4.00 3.97 99.25%
15.00 14.91 99.00%
DPX 90.00 89.95 99.94%
recovery % ± RSD 99.39% ± 0.487
aAverage of three determinations. RSD, relative standard deviation.
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pharmaceutical samples and human plasma with satisfactory
recoveries. In comparison of this proposed sensor to other
analytical technologies such as chromatographic methods, the
developed sensor is cost-eﬀective, fast, potentially portable, and
uses simpler instruments; and because of the outstanding
analytical features of the sensor, the proposed sensor has the
potential to be routinely used in the determination of DPX in
biological samples.
■ EXPERIMENTAL SECTION
Materials and Reagents. DPX and SIL were kindly
supplied by Pharco Pharmaceuticals, Alexandria, Egypt with a
purity of 99.12 and 99.78%, respectively; Joypox tablets, labeled
to contain 60 mg DPX per tablet, were purchased from a local
pharmaceutical supplier (shop). B−R buﬀer (4.0 × 10−2 M)
was prepared by mixing H3PO4, acetic acid, and boric acid with
the appropriate amount of 0.2 M NaOH to obtain the desired
pH (2.0−7.0). Hydrogen-tetrachloroaurate (HAuCl4), potas-
sium permanganate, and sodium nitrate were purchased from
Aldrich Ltd. Cesium chloride was obtained from Sigma-Aldrich.
Fresh human serum was obtained from the blood bank
(VACSERA, Cairo, Egypt). Further details of the instrumenta-
tion utilized are reported in the Supporting Information.
Preparation of the Cesium−Gold Nanoparticle Sen-
sors (Cs−Au/SPE Sensors). SPEs were fabricated at the
Manchester Metropolitan University. We have reported
previously these fabrication steps; see ref 51. The Cs−Au/
SPE sensors were fabricated through the electrochemical
modiﬁcation of the SPEs. Diﬀerent concentrations of Cs, 2.0
× 10−3, 4.0 × 10−3, 6.0 × 10−3, and 8.0 × 10−3 M were
explored. We found that 6.0 × 10−3 M Cs is the optimal
concentration with Au for codeposition. This was performed by
immersing SPEs into a solution comprising 6.0 × 10−3 M
HAuCl4 and CsCl2 in 0.1 M KNO3 at a constant potential of
−0.4 V (vs Ag/AgCl) for 80 s to form the Cs−Au/SPE-based
surface, which forms the basis of the sensor. After this step, the
sensor was washed with bidistilled water and left to dry at 25
°C for 45 min. The Cs−Au/SPEs were then ready to use.
Characterization of the Cs−Au/SPE is reported in the
Supporting Information (Figure S2, SEM images; Figure S3,
energy dispersive X-ray analysis (EDAX)).
Recommended Experimental Procedure. Cs−Au/SPE
sensors were electrochemically cycled between the potentials of
+0.8 and −1.4 V versus Ag/AgCl at a scan rate of 0.1 V s−1
within pH 2.0 B−R buﬀer to determine the voltammetric
current from the baseline to the maximum point.
Analysis of Real Samples. Serum samples were taken
from a healthy individual just before the experiments. Ten
microliters of the supernatant were transferred quantitatively
into a 5 mL volumetric ﬂask spiked with diﬀerent volumes of
DPX and SIL standard solution (1.0 mM) in pH 2.0 B−R
buﬀer solution. The solution was transferred into the
electrochemical cell to be analyzed without any further
pretreatment.
Urine was collected from healthy donors in the morning, free
of interfering drugs. Blank urine samples were collected from
ﬁve subjects, which were then used to prepare urine standards
for validation. Urine standards were prepared by dilution with
pH 2.0 B−R buﬀer solution containing DPX. All urine samples
were prepared and analyzed on the day of collection. All
experiments were performed in compliance with the relevant
laws and institutional guidelines, and the institutional
committees have approved these experiments.
Six capsules of Joypox were mixed and weighed with the
average mass per tablet determined. These were then dissolved
in 50.0 mL of methanol and sonicated for 60 min. The solution
was then ﬁltered into a 25.0 mL volume calibrated ﬂask, and the
residue was washed three times with methanol, added to the
ﬂask, and then diluted to the mark with the same solvent.
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